AM 510
Alternative Names: AM-510; Nimvec™ AM 510Latest Information Update: 19 Jun 2024
At a glance
- Originator Amarna Therapeutics
- Class Antihyperglycaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 17 Jun 2024 Pharmacodynamics data from a preclinical trial in Type 1 diabetes mellitus released by Amarna Therapeutics
- 18 Apr 2024 AM 510 is available for licensing as of 18 Apr 2024. https://www.amarnatherapeutics.com/partners.html
- 12 Apr 2024 Preclinical trials in Type 1 diabetes mellitus in Netherlands (Parenteral), Prior to April 2024 (Amarna Therapeutics pipeline, April 2024)